全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Spruelike Enteropathy Associated with Olmesartan: An Unusual Case of Severe Diarrhea

DOI: 10.1155/2013/618071

Full-Text   Cite this paper   Add to My Lib

Abstract:

A 64-year-old male with a history of hypertension presented with worsening diarrhea and 25-pound weight loss over the preceding three months. Prior screening colonoscopy was unremarkable, and the patient failed conservative management. On presentation, the patient had orthostatic hypotension associated with prerenal azotemia for which olmesartan (40?mg/day) was held. Initial workup for chronic diarrhea was essentially unremarkable. Then, EGD was performed with small bowel biopsy, which showed a moderate villous blunting and an intraepithelial lymphocyte infiltration. Celiac disease was excluded by negative conventional serology tests and the absence of clinical response to a gluten-free diet. In the interim, diarrhea became resolving without any other interventions, and clinical response was achieved even with gluten-containing diet. Two months later, he achieved a complete resolution of diarrhea and regained 20-pound weight. Spruelike enteropathy is a clinical entity manifested by chronic diarrhea and intestinal villous atrophy. Spruelike enteropathy associated with olmesartan as a cause of drug-induced diarrhea is rare, and it has been reported only in a case series to date. This case highlighted the importance for clinicians to maintain a high index of suspicion for olmesartan as a precipitant of spruelike enteropathy. 1. Introduction Olmesartan is one of several angiotensin II receptor blocking (ARB) agents. Olmesartan has been shown to have a longer half-life and a greater effect on systolic blood pressure than other ARB agents, making it widely prescribed for the management of hypertension. Diarrhea is a common adverse effect of many medications, and it is one of the common adverse effects of olmesartan. However, in most cases the mechanisms underlying diarrhea remain unclear. Spruelike enteropathy is a clinical entity manifested by chronic diarrhea and intestinal villous atrophy. Spruelike enteropathy as a cause of drug-induced diarrhea has been recognized in posttransplant patients while taking immunosuppressive medications [1–3]. Subsequently, a case series of spruelike enteropathy associated with olmesartan in transplant-na?ve patients has recently been reported from a tertiary referral center [4], but no similar reports have been reported to date. 2. Case Presentation A 64-year-old male with a past medical history of hypertension presented with worsening diarrhea and 25-pound weight loss over the preceding three months. He reported 5–10 daily episodes of watery, nonbloody diarrhea associated with abdominal bloating. The patient failed

References

[1]  T. R. Ziegler, C. Fernández-Estívariz, L. H. Gu, et al., “Severe villus atrophy and chronic malabsorption induced by azathioprine,” Gastroenterology, vol. 124, pp. 1950–1957, 2003.
[2]  N. Kamar, P. Faure, E. Dupuis et al., “Villous atrophy induced by mycophenolate mofetil in renal-transplant patients,” Transplant International, vol. 17, no. 8, pp. 463–467, 2004.
[3]  H. Weclawiak, A. Ould-Mohamed, B. Bournet et al., “Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation,” American Journal of Transplantation, vol. 11, no. 3, pp. 575–582, 2011.
[4]  A. Rubio-Tapia, M. L. Herman, J. F. Ludvigsson, et al., “Severe spruelike enteropathy associated with olmesartan,” Mayo Clinic Proceedings, vol. 87, pp. 732–738, 2012.
[5]  A. Rostom, C. Dube, A. Cranney, et al., “Celiac disease,” Evidence Report Technology Assessment, vol. 104, pp. 1–6, 2004.
[6]  A. Rostom, J. A. Murray, and M. F. Kagnoff, “American gastroenterological association (AGA) institute technical review on the diagnosis and management of celiac disease,” Gastroenterology, vol. 131, no. 6, pp. 1981–2002, 2006.
[7]  S. Takai, D. Jin, and M. Miyazaki, “New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage,” Journal of Pharmacological Sciences, vol. 113, no. 4, pp. 301–309, 2010.
[8]  L. A. Feagins, “Role of transforming growth factor-β in inflammatory bowel disease and colitis-associated colon cancer,” Inflammatory Bowel Diseases, vol. 16, no. 11, pp. 1963–1968, 2010.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133